Regulated Information

Period

Filter by

Reset

Showing: 1 – 05 of 171 Regulated Information

Show

Sort

Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook

07 December 2023

Capital Markets Day 2023 – Ipsen outlines next phase of growth & transformation and provides new mid-term outlook

PARIS, FRANCE, 7 December 2023 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today holds its Capital Markets Day in London, U.K.

IPSEN - Buy-back programme - Art 5 of MAR - Week 45 - 2023

14 November 2023

IPSEN – Buy-back programme – Art 5 of MAR – Week 45 – 2023

Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine

13 November 2023

Download Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine

Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine

PARIS, FRANCE, 13 November, 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced full results from the pivotal Phase III ELATIVE® trial, which are being presented in a late-breaking oral session (Abstract #484, Monday,…

IPSEN - Buy-back programme - Art 5 of MAR - Week 44 - 2023

07 November 2023

IPSEN – Buy-back programme – Art 5 of MAR – Week 44 – 2023

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

06 November 2023

Ipsen – Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital

1 … 18 19 20 21 22 23 24 … 35